Quarterly Result15 May 2026, 01:20 pm
Solara Active Pharma: Audited Results for FY26 Approved
AI Summary
Solara Active Pharma Sciences Ltd. has announced the approval of audited standalone and consolidated financial results for the year ended March 31, 2026. The decision was made during a board meeting held on May 15, 2026, following the recommendation of the Audit Committee. The board also took on record the unmodified opinions from the Statutory Auditors, M/s. Deloitte Haskins & Sells LLP, regarding the audited financial results. The results are available on the company's website.
Key Highlights
- Audited standalone and consolidated financial results for FY26 approved.
- Unaudited results for the quarter ended March 31, 2026, were also approved.
- Auditors' Report with unmodified opinion issued by Deloitte Haskins & Sells LLP.
- Board meeting commenced at 12.00 P.M and concluded at 12.50 P.M.
Price Impact
More from SOLARA